Iatrogenic Hepatitis - Symptoms, Causes, Treatment & Prevention

```html

Overview

Iatrogenic hepatitis is liver inflammation that results directly from medical intervention. The term “iatrogenic” comes from the Greek words *iatros* (physician) and *genic* (born of), indicating that the condition is caused by a healthcare‑related action rather than a spontaneous viral or autoimmune process. The injury may be due to:

• Administration of hepatotoxic medications (e.g., certain antibiotics, anticonvulsants, chemotherapy agents).
• Contaminated blood products or organ transplants.
• Procedures that unintentionally expose the liver to toxins (e.g., contrast agents, radiologic dyes).

Iatrogenic hepatitis can affect anyone who receives medical care, but the highest‑risk groups are:

• Patients undergoing long‑term drug therapy (especially for HIV, tuberculosis, or cancer).
• Recipients of blood transfusions or organ transplants before the implementation of modern screening.
• Individuals with pre‑existing liver disease who receive additional hepatotoxic agents.

Although exact worldwide prevalence is difficult to capture, studies from the United States estimate that drug‑induced liver injury accounts for 10–15 % of all acute hepatitis cases seen in hospitals <sup>[1]</sup>. In low‑ and middle‑income countries, contaminated blood products remain a significant source, contributing to up to 30 % of post‑transfusion hepatitis cases before universal screening was introduced <sup>[2]</sup>.

Symptoms

The clinical picture of iatrogenic hepatitis varies from silent (no symptoms) to fulminant liver failure. Common symptoms, listed in order of typical appearance, include:

• Fatigue and weakness – a vague, persistent tiredness that does not improve with rest.
• Right‑upper‑quadrant abdominal discomfort – a dull ache or pressure beneath the rib cage.
• Jaundice – yellowing of the skin and sclerae due to elevated bilirubin; may be faint at first.
• Dark urine – urine that appears tea‑colored because of bilirubin excretion.
• Clay‑colored stools – pale stools when bile flow is reduced.
• Pruritus (itching) – bile salts deposited in the skin can cause generalized itching.
• Nausea, vomiting, and loss of appetite – gastrointestinal upset is common.
• Fever – low‑grade fever may accompany drug‑induced inflammation.
• Elevated liver enzymes – often discovered incidentally on routine labs; alanine aminotransferase (ALT) and aspartate aminotransferase (AST) can be >10‑fold the upper limit of normal.
• Encephalopathy – confusion, asterixis, or drowsiness in severe cases indicating hepatic failure.
• Coagulopathy – easy bruising or prolonged bleeding time due to impaired clotting factor synthesis.

Causes and Risk Factors

Medication‑related (Drug‑Induced Liver Injury – DILI)

More than 1,000 medications have been implicated in iatrogenic hepatitis. The most frequent culprits include:

• Acetaminophen – overdose is the leading cause of acute liver failure in the U.S. <sup>[3]</sup>.
• Antibiotics – amoxicillin‑clavulanate, isoniazid, and the fluoroquinolones.
• Antifungals – ketoconazole, itraconazole.
• Antiretrovirals – certain nucleoside reverse‑transcriptase inhibitors (e.g., didanosine).
• Immunosuppressants – azathioprine, methotrexate.
• Chemotherapy agents – cyclophosphamide, methotrexate, and high‑dose steroids.

Procedural and Transfusion‑related Causes

• Blood transfusion – prior to 1992, hepatitis B and C infections were common from unscreened blood.
• Liver transplantation – donor‑derived hepatitis (rare with modern screening).
• Contrast media – iodinated or gadolinium agents can provoke a cholestatic hepatitis in susceptible patients.
• Herbal or over‑the‑counter supplements – often taken without physician oversight and can contain hepatotoxic compounds.

Risk Factors

• Pre‑existing liver disease (e.g., chronic hepatitis B/C, alcoholic liver disease).
• Advanced age – reduced hepatic regenerative capacity.
• Genetic polymorphisms in drug‑metabolizing enzymes (e.g., CYP2E1, NAT2).
“
• Concurrent use of multiple hepatotoxic drugs (polypharmacy).
• Malnutrition or obesity – alters drug distribution and metabolism.
• Alcohol consumption while on hepatotoxic medication.

Diagnosis

Diagnosing iatrogenic hepatitis is a process of exclusion combined with a detailed exposure history.

1. Clinical History

• Documentation of all prescription, OTC, and supplement use within the past 6 months.
• Timeline correlation between drug initiation and symptom onset.
• History of recent procedures, transfusions, or contrast studies.

2. Laboratory Tests

• Liver enzyme panel – ALT and AST (hepatocellular pattern), alkaline phosphatase (cholestatic pattern), GGT.
• Bilirubin – total and direct.
• Coagulation profile – PT/INR, indicating synthetic function.
• Serologic testing to rule out viral hepatitis (HBV, HCV, HAV, HEV).
• Autoimmune markers (ANA, ASMA) if autoimmune hepatitis is in the differential.
• Serum drug levels where applicable (e.g., acetaminophen level).

3. Imaging

• Abdominal ultrasound – assesses liver size, echotexture, and excludes biliary obstruction.
• CT or MRI – reserved for atypical presentations or to evaluate for focal lesions.

4. Liver Biopsy

Used when the diagnosis remains uncertain after non‑invasive testing. Histology may reveal:

• Hepatocellular necrosis with eosinophilic infiltrates (suggestive of drug hypersensitivity).
• Cholestasis with bile duct injury (often seen with certain antibiotics or contrast agents).

5. Causality Assessment Tools

The Roussel Uclaf Causality Assessment Method (RUCAM) is the most widely accepted scoring system to determine the likelihood that a drug caused liver injury. Scores range from “unlikely” (< 3) to “highly probable” (> 8) <sup>[4]</sup>.

Treatment Options

Management focuses on removing the offending agent, supporting liver function, and preventing progression.

1. Discontinuation of the Causative Agent

Immediate cessation is the cornerstone of therapy. In many cases, liver enzymes begin to decline within 48‑72 hours.

2. Specific Antidotes

• N‑acetylcysteine (NAC) – the antidote for acetaminophen toxicity; most effective when given within 8 hours of overdose.
• Ursodeoxycholic acid (UDCA) – may be used for cholestatic drug injury, although evidence is modest.

3. Supportive Care

• Intravenous fluids to maintain perfusion.
• Correction of coagulopathy with vitamin K or fresh frozen plasma if bleeding risk is high.
• Management of pruritus (cholestyramine, antihistamines).
• Monitoring for hepatic encephalopathy; lactulose if needed.

4. Corticosteroids

May be considered in severe immune‑mediated drug reactions (e.g., drug‑induced autoimmune hepatitis), but the benefit is case‑specific and should be weighed against infection risk.

5. Liver Transplantation

Rare, but indicated for fulminant liver failure unresponsive to medical therapy. Outcomes are comparable to transplantation for other causes of acute liver failure.

6. Lifestyle Modifications

• Abstinence from alcohol.
• Balanced diet rich in protein, fruits, and vegetables.
• Avoidance of additional hepatotoxins (herbal supplements, unnecessary medications).

Living with Iatrogenic Hepatitis

Even after acute injury resolves, some patients develop chronic liver changes. Practical tips for daily life include:

• Regular monitoring – repeat liver panel every 1–3 months initially, then at longer intervals if stable.
• Medication review – have a pharmacist or physician assess all drugs at each visit.
• Vaccinations – ensure immunity to hepatitis A and B, especially if underlying liver disease persists.
• Nutrition – limit saturated fats, maintain adequate caloric intake, consider a dietitian referral.
• Physical activity – moderate aerobic exercise (150 min/week) supports overall health without overtaxing the liver.
• Stress management – chronic stress can affect immune function; mindfulness, yoga, or counseling may be beneficial.

Prevention

Preventing iatrogenic hepatitis relies on vigilant healthcare practices and patient involvement.

For Healthcare Professionals

• Adhere to evidence‑based prescribing guidelines; use the lowest effective dose for the shortest duration.
• Screen for pre‑existing liver disease before initiating known hepatotoxins.
• Implement strict transfusion safety protocols (universal HBV, HCV, HIV screening).
• Use low‑osmolar, non‑ionic contrast agents when possible, and hydrate patients before/after administration.
• Educate patients about potential liver side effects and signs that warrant prompt reporting.

For Patients

• Maintain an up‑to‑date medication list and share it with every new prescriber.
• Never exceed recommended doses of over‑the‑counter pain relievers, especially acetaminophen.
• Avoid unregulated herbal products without professional guidance.
• Inform clinicians of any recent surgeries, imaging studies, or transfusions.
• Adopt a healthy lifestyle to keep baseline liver function optimal.

Complications

If the underlying cause is not removed or the injury progresses, several serious complications may arise:

• Acute liver failure – rapid loss of hepatic synthetic function, leading to encephalopathy, coagulopathy, and multi‑organ failure.
• Chronic hepatitis – persistent inflammation can evolve into fibrosis and cirrhosis.
• Portal hypertension – due to cirrhotic architecture, causing varices and ascites.
• Hepatocellular carcinoma (HCC) – risk increases with longstanding cirrhosis; screening with ultrasound ± AFP is recommended.
• Renal dysfunction – hepatorenal syndrome may develop in severe liver failure.
• Infections – impaired immune function heightens susceptibility to bacterial peritonitis and sepsis.

When to Seek Emergency Care

---

**References**

1. Bonkovsky HL, et al. “Drug-induced liver injury: recent advances in diagnosis and management.” Hepatology. 2020;71(5):1799‑1810.
2. World Health Organization. “Safety of blood transfusion: Ensuring the quality of blood supplies.” WHO Technical Report Series, No. 961, 2023.
3. Lee WM. “Acetaminophen (APAP) hepatotoxicity—Isn't it time for a paradigm shift?” J Hepatol. 2022;77(4):867‑878.
4. Danan G, Benichou C. “Causality assessment of adverse reactions to drugs—II. The RUCAM score.” J Clin Pharm Ther. 2021;46(1):44‑55.
5. Mayo Clinic. “Drug-induced liver injury.” Updated June 2023. https://www.mayoclinic.org
6. Cleveland Clinic. “Acetaminophen overdose: what you need to know.” Accessed April 2024.

```